TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy… Read More..

Ray Stachowiak Becomes Executive Chairman, Peter Gaccione Appointed CEO- -Craig Tagawa Remains President, Search Underway for CFO- -AMS Books First Order of 2023- SAN FRANCISCO, CA, March 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for… Read More..

Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced initiation of a second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently receiving off-label systemic therapy Continued advancement of pipeline products with Queensland University of Technology towards potential initiation… Read More..